Clinical Trial Update: Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Gallium-68 labeled PSMA-11 PET/CT for detecting recurrent prostate cancer after initial therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Carcinoma

Drugs mentioned

• Gallium Ga-68 labeled PSMA-11 (Ga-68 PSMA-11)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 3 | Status: COMPLETED